Twist Bioscience (NASDAQ:TWST) CFO Sells $96,541.88 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 2,738 shares of Twist Bioscience stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $35.26, for a total transaction of $96,541.88. Following the transaction, the chief financial officer owned 140,031 shares of the company’s stock, valued at approximately $4,937,493.06. The trade was a 1.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Adam Laponis also recently made the following trade(s):

• On Thursday, October 30th, Adam Laponis sold 5,517 shares of Twist Bioscience stock. The stock was sold at an average price of $31.44, for a total transaction of $173,454.48.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock traded up $2.18 during trading on Tuesday, hitting $40.22. 1,983,974 shares of the company were exchanged, compared to its average volume of 1,480,279. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $55.33. The company has a quick ratio of 3.33, a current ratio of 3.64 and a debt-to-equity ratio of 0.03. The firm has a 50 day moving average price of $31.62 and a 200 day moving average price of $31.11. The stock has a market capitalization of $2.46 billion, a price-to-earnings ratio of -30.70 and a beta of 2.19.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.05). Twist Bioscience had a negative return on equity of 27.40% and a negative net margin of 20.63%.The company had revenue of $99.01 million for the quarter, compared to analysts’ expectations of $97.40 million. On average, equities analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on TWST shares. Evercore ISI reaffirmed an “outperform” rating and set a $42.00 price target on shares of Twist Bioscience in a research note on Monday, January 5th. TD Cowen raised their target price on shares of Twist Bioscience from $32.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Twist Bioscience in a research report on Monday, December 29th. Finally, Barclays increased their target price on Twist Bioscience from $37.00 to $39.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Nine analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.67.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Strs Ohio purchased a new stake in Twist Bioscience during the 1st quarter worth $711,000. American Century Companies Inc. lifted its stake in shares of Twist Bioscience by 13.2% during the second quarter. American Century Companies Inc. now owns 864,384 shares of the company’s stock worth $31,801,000 after purchasing an additional 100,978 shares in the last quarter. Squarepoint Ops LLC boosted its position in shares of Twist Bioscience by 192.8% in the second quarter. Squarepoint Ops LLC now owns 71,708 shares of the company’s stock worth $2,638,000 after buying an additional 47,221 shares during the period. Conestoga Capital Advisors LLC purchased a new stake in shares of Twist Bioscience during the 2nd quarter valued at about $1,044,000. Finally, Capital Fund Management S.A. purchased a new stake in shares of Twist Bioscience during the 2nd quarter valued at about $2,507,000.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.